Bio-Techne
TECH
72.67
-0.03
-0.04%
Bio-Techne
US · TECH
#1365 by market cap
Listed 1970
72.67
-0.03
-0.04%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
Recent news
-
Rating change
A Quick Look at Today's Ratings for ODDITY Tech(ODD.US), With a Forecast Between $10 to $21Market Newswire · 2026/11/13
-
Company notice
NASN TECH: (1) CHANGE OF JOINT COMPANY SECRETARY,AUTHORISED REPRESENTATIVE AND PROCESS AGENT;(2) WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND8.17 OF THE LISTING RULES;AND(3) CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONGHKEX · 2026/11/13
-
Analysts: U.S. tech stocks under pressure, European equities relatively resilientLatest · 2026/11/14
-
Following Jensen Huang's departure, "The Big Short" investor doubles down on shorting tech stocks, warning that the AI boom may be a "bull trap."wallstreetcn · 2026/11/14
-
Datadog vs. DocuSign: Which Tech Stock Is a Better Buy Heading Into 2027?HK MoneyClub · 2026/11/13
-
Company notice
Hangzhou High-Tech: Report on the Issuance of Shares to Specific Investors and Listing on the ChiNext Board by Hangzhou High-Tech Materials Technology Co., Ltd.SZSI · 2026/11/13
-
Rating change
Goldman Sachs Maintains ODDITY Tech(ODD.US) With Sell Rating, Raises Target Price to $10Market Newswire · 2026/11/12
-
Rating change
Barclays Maintains ODDITY Tech(ODD.US) With Sell Rating, Raises Target Price to $15Market Newswire · 2026/11/11
-
Rating change
Craig-Hallum Maintains Health in Tech(HIT.US) With Buy Rating, Cuts Target Price to $2Market Newswire · 2026/11/13
-
Rating change
RBC Capital Maintains Bio-Techne(TECH.US) With Hold Rating, Maintains Target Price $73Market Newswire · 2026/11/10
-
Company notice
Hangzhou High-Tech: Legal Opinion of Zhejiang TianCe Law Firm on the Compliance of the Issuance Process and Subscribers for the 2026 Offering of A-Shares to Specific Investors by Hangzhou High-Tech Materials Technology Co., Ltd.SZSI · 2026/11/13
-
Maxim Group Maintains Health in Tech(HIT.US) With Buy Rating, Cuts Target Price to $1Market Newswire · 2026/11/13
-
Rating change
J.P. Morgan Initiates ODDITY Tech(ODD.US) With Hold Rating, Announces Target Price $20Market Newswire · 2026/11/14
-
Rating change
KeyBanc Maintains Tetra Tech Inc(TTEK.US) With Buy Rating, Raises Target Price to $42Market Newswire · 2026/11/13
-
Rating change
Goldman Sachs Maintains CHINA RES BUILDING MATLS TECH HLDGS(CJRCF.US) With Sell Rating, Cuts Target Price to $0.09Market Newswire · 2026/11/10
-
Company notice
Hangzhou High-Tech: Report by Zhongde Securities Co., Ltd. on the Compliance of the Share Issuance Process and Subscribers for Hangzhou High-Tech Materials Technology Co., Ltd.'s Private PlacementSZSI · 2026/11/13
-
Rating change
Baird Maintains Tetra Tech Inc(TTEK.US) With Hold Rating, Raises Target Price to $40Market Newswire · 2026/11/12
-
Company notice
Jinhai High-Tech: Legal Opinion of Shanghai Duan & Duan Law Firm on the Third Extraordinary Shareholders' Meeting of Zhejiang Jinhai High-Tech Co., Ltd. for 2026SZSI · 2026/11/14
-
Maxim Group Maintains Tetra Tech Inc(TTEK.US) With Hold RatingMarket Newswire · 2026/11/15
-
Rating change
Truist Financial Maintains ODDITY Tech(ODD.US) With Hold Rating, Raises Target Price to $20Market Newswire · 2026/11/12
-
Rating change
Argus Research Downgrades Bio-Techne(TECH.US) to Sell RatingMarket Newswire · 2026/10/27
-
AI Boom Faces Scrutiny Over Returns; Earnings Reports from U.S. Tech Giants Trigger Market PlungeGlobal Market Report · 2026/11/1
-
AI-driven dip-buying strategies fail this time? Tech stocks face severe penalties following earnings misses, while U.S. equity volatility surges.Zhitong Finance · 2026/10/31
-
Company notice
SILTRIUM TECH CORP. | 10-K: Annual reportSEC · 2026/10/30
-
Elizabeth Warren Slams Trump's Voluntary AI Safety Deal With Tech CEOs, Says Republicans Aren't Doing Enough to Regulate AI: 'Not Lifting A Finger...'Benzinga · 2026/10/31
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:01:25 · For reference only, not investment advice and not tailored to your situation.
Bio-Techne discussion 0 comments